Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
The aim of this post-marketing observational study is to obtain further data on the
 evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with
 Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) after
 unsustainable clinical response to disease modifying antirheumatic drugs (DMARD) and or
 biological disease modifying antirheumatic drugs (BDMARD). Treatment strategies in moderate
 to severe rheumatoid arthritis, psoriatic arthritis and in severe active ankylosing
 spondylitis commonly consist of introducing biologics after conventional disease modifying
 antirheumatic drugs or non steroidal antiinflammatory drugs fail. Although biologic disease
 modifying antirheumatic drugs are generally well-tolerated, intolerances may develop or
 efficacy may diminish, at which time another biologic disease modifying antirheumatic drug
 might be considered. This study shall evaluate the quality of life outcomes of HUMIRA®, given
 after conventional disease modifying antirheumatic drugs and or non antiinflammatory drug
 failures and or after biological disease modifying antirheumatic drug failures . Failure in
 this context means primary or secondary loss of efficacy or intolerance to the initial agent.
Inclusion Criteria:

 -  Patients age greater than or equal to 18

 -  Patients must fulfill international and national guidelines for use of a BDMARD in RA,
 PsA and AS (Chest X-ray and purified protein derivative (PPD) skin test negative for
 tuberculosis).

 In addition one of the following criteria must be fulfilled:

 -  unsatisfactory DMARD response defined as failure to treatment with at least two DMARDs
 including Methotrexate in patients with RA or PsA

 -  unsatisfactory NSAID response in patients with AS or

 -  unsatisfactory response to prior BDMARDs (in this case patients must have received
 BDMARDs at least 12 weeks before visit 1) in patients with RA or PsA or AS.

 Exclusion Criteria:

 -  Patients who meet contraindications as outlined in the latest version of the Humira
 syringe® Summary of Product Characteristics (SmPC) and Humira Pen® SmPC

 -  Patients participating in another study or clinical trial.